Skip to main content
SpringerLink
Log in

Biologics in Interstitial Lung Diseases in Rheumatological Disorders

  • Chapter
  • First Online:
Handbook of Biologics for Rheumatological Disorders

  • 718 Accesses

Abstract

Interstitial lung disease (ILD) is an inflammatory condition of the lung parenchyma. It is the commonest form of pulmonary involvement in systemic autoimmune rheumatic diseases (SARDs). Biologic disease modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of various SARDs. Because of the inflammatory nature of ILD, bDMARDs have also been tried in its treatment. No formal guidelines exist on the use of bDMARDs in the treatment of ILD. Available literature shows conflicting results about the efficacy and safety of bDMARDs in ILD. Moreover, many of the commonly used bDMARDs have been shown to induce or worsen pre-existing ILD. We discuss in this chapter the current status of bDMARDs in the treatment of ILD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2009;13:1866–76.

    Article  Google Scholar 

  2. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25:23–8.

    CAS  Google Scholar 

  3. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83:218–2.

    Article  CAS  Google Scholar 

  4. Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int. 2012;32:3587–90.

    Article  CAS  Google Scholar 

  5. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis. 2011;41:256–64.

    Article  CAS  Google Scholar 

  6. Dixon WG, Hyrich KL, Watson KD, Lunt M. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–91.

    Article  CAS  Google Scholar 

  7. Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:622–8.

    Google Scholar 

  8. Horai Y, Miyamura T, Shimada K, et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther. 2012;37:117–21.

    Article  CAS  Google Scholar 

  9. Dias OM, Pereira DA, Baldi BG, et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol. 2014;40:77–81.

    Article  Google Scholar 

  10. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.

    Article  CAS  Google Scholar 

  11. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343–51.

    Article  Google Scholar 

  12. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22:498–508.

    Article  CAS  Google Scholar 

  13. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol. 2003;170:567–74.

    Article  CAS  Google Scholar 

  14. Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum. 2010;40:147–63.

    Article  CAS  Google Scholar 

  15. Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009;30:275–6.

    Article  Google Scholar 

  16. Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-alpha therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013;22:394–402.

    Article  CAS  Google Scholar 

  17. Fitzgerald DB, Moloney F, Twomey M, et al. Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:215–21.

    Google Scholar 

  18. Kabia A, Md Yusof MY, Dass S, Vital E, Beirne P, Emery P. Efficacy and safety of rituximab in rheumatoid arthritis patients with concomitant interstitial lung disease: 10-year experience at single centre. Rheumatology. 2015;54:i86.

    Google Scholar 

  19. Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology. 2016;55:1318–24.

    Article  CAS  Google Scholar 

  20. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment refractory interstitial lung disease. Respirology. 2014;19:353–9.

    Article  Google Scholar 

  21. Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40:787–97.

    Article  CAS  Google Scholar 

  22. Keidel SM, Hoyles RK, Wilkinson NM. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatology. 2014;53:573–4.

    Article  Google Scholar 

  23. Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol. 2011;40:400–1.

    Article  CAS  Google Scholar 

  24. Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77:212–20.

    Article  CAS  Google Scholar 

  25. Kawashiri SY, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32:4023–6.

    Article  Google Scholar 

  26. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 2016;36:881–9.

    Article  CAS  Google Scholar 

  27. Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73:1591–3.

    Article  CAS  Google Scholar 

  28. Donahoe M, Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10:e0127771.

    Article  Google Scholar 

  29. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Critic Care Med. 2008;178:948–55.

    Article  CAS  Google Scholar 

  30. Parker JM, Glaspole IN, Lancaster LH, et al. A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Resp Crit Care Med. 2018;197:94–103.

    Article  CAS  Google Scholar 

  31. Swigris JJ, Ogura T, Scholand MB, et al. The RIFF study (cohort A): a phase II, randomized, double-blind, placebo-controlled trial of Lebrikizumab as monotherapy in patients with idiopathic pulmonary fibrosis. Am J Resp Crit Care Med. 2018;197:A6167.

    Google Scholar 

  32. Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Resp J. 2016;47:1481–91.

    Article  Google Scholar 

  33. Raghu G, Scholand M, Andrade JDE, et al. Safety and efficacy of anti-CTGF monoclonal antibody FG-3019 for the treatment of idiopathic pulmonary fibrosis (IPF): results of Phase 2 clinical trial two years after initiation. Am J Resp Crit Care Med. 2014;189:A1426.

    Google Scholar 

  34. Raghu G, Richeldi L, Crestani B, et al. Safety and efficacy of SAR156597 in idiopathic pulmonary fibrosis (IPF): a phase 2, randomized, double-blind, placebo-controlled study. Am J Resp Crit Care Med. 2018;197:A2441.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Fortis Flt Lt Rajan Dhall Hospital, New Delhi, India

    Ashish Sharma & Ashok Kumar

Authors
  1. Ashish Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashok Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashok Kumar .

Editor information

Editors and Affiliations

  1. Sir Ganga Ram Hospital, New Delhi, India

    Neeraj Jain  & Lalit Duggal  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, A., Kumar, A. (2022). Biologics in Interstitial Lung Diseases in Rheumatological Disorders. In: Jain, N., Duggal, L. (eds) Handbook of Biologics for Rheumatological Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-16-7200-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-7200-2_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-7199-9

  • Online ISBN: 978-981-16-7200-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation